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Abstract: With the aging population and high prevalence of atherosclerosis, an increasing number of patients presenting 
with heart failure and angina are found to have severe coronary artery disease and severe valvular disease. These patients 
tend to have multiple co-morbidities such as end stage renal disease and are considered high-risk for surgery. In patients 
with severe coronary artery disease, severe aortic stenosis, and heart failure with depressed left ventricular systolic 
function, the options are limited as they are not usually offered surgery, but palliative percutaneous high-risk procedures 
might be a viable alternative.  
Though long term results after balloon aortic valvuolpasty are not promising, there is a role for these procedures in high-
risk inoperable patients for either palliation or as a bridge to surgery. Unprotected left main percutaneous interventions are 
also feasible with low complication rates. This review provides mounting evidence that it is reasonable to perform 
combined palliative balloon aortic valvuolpasty and high-risk coronary artery stenting in certain inoperable patients. An 
illustrative case is presented that extends the findings of the current literature and demonstrates that combined balloon 
aortic valvuolpasty and left main stenting could be a safe and effective alternative in the setting of heart failure, left 
ventricular dysfunction, and end stage renal disease.  
Keywords: Aortic stenosis, critical left main disease, percutaneous balloon aortic valvuoplasty, unprotected left main stenting, 
palliative high risk percutaneous interventions. 
CASE REPORT 
  A 56 year-old African American female with end stage 
renal disease on hemodialysis was admitted for worsening 
dsypnea and exertional chest pain. Her shortness of breath 
had begun 1-2 years ago but had progressed rapidly over the 
past few months. Presently she has dyspnea on exertion with 
minimal activity, severe orthopnea, paroxysmal nocturnal 
dyspnea, and marked peripheral edema and was considered 
to be in New York Heart Association class IV heart failure. 
  Past medical history was notable for congestive heart 
failure with preserved left ventricular (LV) function, end 
stage renal disease on hemodialysis, systemic arterial hyper-
tension, and diabetes type 2. On admission the patient was 
on a beta blocker, ace inhibitor, non-dihydropyridine cal-
cium channel blocker, hydralazine, a statin, and aspirin. 
  She was afebrile with a heart rate of 94 beats/min, blood 
pressure 148/75 mm Hg, and a respiratory rate 28 
breaths/min with 94% oxygen saturation on room air. Her 
exam was otherwise notable for jugular venous pressure at 
about 13 cm H20, delayed carotid upstrokes, and bibasilar 
crackles. Cardiac exam was notable for a normal S1 and a 
soft P2, a focal, non-displaced point of maximal impulse 
with no lifts, heaves, or thrills, and a III/VI systolic ejection 
murmur that peaked late in systole and was audible at the  
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right upper sternal border; No rubs or gallops were noted. 
Extremity exam revealed marked peripheral edema. 
  Transthoracic echocardiography revealed a LV ejection 
fraction of 35%, preserved right ventricular function, mild 
mitral regurgitation, moderate tricuspid regurgitation, a 
heavily calcified aortic valve with three leaflets, and severe 
aortic stenosis (AS) (Fig. 1). Her pulmonary artery systolic 
pressure was severely elevated at 86 mm Hg and was 
calculated by the peak tricuspid regurgitation jet using the 
simplified Bernoulli equation.  
  Left and right heart catheterizations were performed and 
were remarkable for severe ostial left anterior descending 
(LAD) coronary artery disease with distal left main (LM) 
involvement (Fig. 2), minimal left circumflex and right 
coronary artery disease, a right atrial pressure of 14 mm Hg, 
pulmonary artery pressure of 67/29 with a mean of 45 mm 
Hg, and a pulmonary capillary wedge pressure of 23 mm Hg; 
Left ventricular pressure was 143/18 mm Hg, and aortic 
pressure was 85/43 mm Hg with an aortic valve mean 
gradient of 56 mm Hg.  
  Given the constellation of severe heart failure, severe AS, 
and severe ostial LAD disease with distal LM involvement, 
cardiovascular surgery was consulted for a potential aortic 
valve replacement (AVR) and coronary artery bypass 
grafting, but the patient was considered a poor surgical can-
didate due to end stage kidney disease and elevated pulmo-
nary arterial pressures and was treated initially with optimal 
medical management.  
















Fig. (1). 2-dimensional echocardiography reveals a calcified aortic 
valve with a max velocity of 4.4 m/sec, a mean velocity of 3.4 
m/sec, a max gradient of 73 mm Hg with a mean gradient of 47 mm 


















Fig. (2). Coronary angiography in the RAO caudal projection 
demonstrates a distal 60-70% LM stenosis, and a 95% ostial 
stenosis of the LAD. 
 
  However, the patient went into cardiogenic shock and 
was unable to tolerate dialysis. Emergent measures were 
discussed, and after much deliberation between the patient 
and her family, the patient elected to undergo high-risk 
percutaneous balloon aortic valvuloplasty (BAV) and 
stenting of an unprotected LM and LAD. BAV was 
performed with a 25 mm x 6.0 cm balloon dilation catheter 
(Z-Med II
TM), which was placed across the aortic valve. 
After 2 inflations, there was a marked reduction in the LV-
aortic gradient (Fig. 3). After the second inflation, the patient 
went into ventricular fibrillation and was stabilized with 
multiple DC cardioversions and emergent intubation with 
mechanical ventilation. Coronary angioplasty and stenting of 


















Fig. (3). Using rapid right ventricular pacing at 160 beats/minute, 
BAV was performed with a 25 mm x 6.0 cm balloon dilation 
catheter (Z-Med IITM). After 2 inflations across the aortic valve, 
the waist on the balloon disappeared, and the LV-aortic gradient 

















Fig. (4). Following LM and LAD angioplasty and stenting, the 
kissing balloon technique was performed on the LAD and left 
circumflex artery with excellent results. Palliative Combined Percutaneous Balloon Aortic Valvuloplasty  Current Cardiology Reviews, 2010, Vol. 6, No. 1    43 
  The patient was extubated within 48 hours, and her 
volume status was optimized prior to being discharged to 
home in stable condition. At 6-month follow-up, she was in 
New York Heart Association class II heart failure with a 
markedly improved exercise capacity and was free of chest 
pain. 
DISCUSSION  
  The incidence of co-existing severe AS and LM disease 
is unknown, but is believed to be rising and presents a 
tremendous challenge to patients and clinicians [1]. If the 
patient is a poor surgical candidate due to multiple co-
morbidities, the remaining options are primarily palliative in 
nature. 
  LM stenting is a viable option in inoperable candidates 
and is associated with high rates of technical success, low 
procedural risk, and low rates of cardiac death (11.9%) at 3 
year follow-up [2]. The need for repeat
  revascularization 
might be as high as 23.9% according to a recent experience 
including 67 patients [2].  
  Recently a large non-randomized trial compared 1102 
patients with unprotected LM disease who underwent 
stenting and 1138 patients who underwent coronary artery 
bypass grafting. At 3 years, the risk of restenosis requiring 
target-vessel revascularization was significantly higher in 
patients that received stents than in those who underwent 
surgical revascularization, but there was no significant 
difference in the risk of death or in the cumulative endpoint 
of death, myocardial infarction, or stroke between the two 
groups. While the need for repeat revascularization was 
greater after bare metal stent implantation as compared to 
drug-eluting stents, there was a slight increase in death and 
in the composite end point in those patients that received 
drug-eluting stents [3]. Additional studies have also 
compared drug-eluting stents and bare metals stents in the 
setting of unprotected LM interventions. 220 patients with 
unprotected LM disease underwent drug-eluting stent 
implantation and were compared with a historical control, 
which included 224 patients who received bare metal stents. 
At 15-month follow-up, the incidence of target-lesion 
revascularization, major adverse cardiac events, and cardiac 
death were significantly lower after drug-eluting stent 
implantation [4]. Drug-eluting stents and bare metal stents 
have even been compared in patients with severe unprotected 
LM coronary artery disease in the setting of an acute coro-
nary syndrome, and while drug-eluting stent implantation 
resulted in less myocardial infarction and less target-vessel 
revascularization than bare metal stents, mortality was 
similar between the two groups [5]. A randomized trial 
which included over 600 patients who underwent unpro-
tected LM stenting showed that there was no clinical or 
angiographic difference observed after implantation with 
either a Paclitaxel or a Sirolimus stent [6]. 
  Indications for percutaneous BAV are limited due to 
short-term benefit, high complication rates, and a high risk 
of restenosis [7], but it remains a reasonable option in certain 
patients. BAV fractures the calcific deposits on the
  valve 
leaflets, minimally stretches the annulus,
  and mildly 
separates the commissures [8, 9]. This results in a moderate 
increase in aortic valve area, a modest reduction in
  the 
transvalvular pressure gradient, and a mild increase in LV 
systolic function [8, 9]. Following BAV the aortic valve
 area 
is infrequently greater than 1.0 cm
2, and BAV is associated 
with a 10% rate of severe acute complications. While the 
majority of patients report symptomatic improvement after 
BAV, there is a tendency for clinical deterioration within 6-
12 months due to a high likelihood of restenosis [8]. 
  144 patients with severe AS were treated with BAV after 
they were not offered AVR due to high surgical risk. 57% 
did not require additional treatment (group 1). Repeat BAV 
was performed in 19% of patients secondary to restenosis 
(group 2), and AVR was done in the remaining 24% of cases 
(group 3). Survival at 3 years from the date of the last 
intervention was 13%, 20%, and 75% for group 1, 2, and 3 
respectively [7].  
  Certainly, AVR is superior to BAV and is indicated for 
symptomatic patients with severe
  AS and in patients
  with 
severe AS and decreased LV systolic
 function (EF <50%). 
According to the present ACC/AHA guidelines, BAV is not 
recommended as an
  alternative
  to AVR for patients with 
severe AS, but is a reasonable option as
 a bridge to
 AVR in 
hemodynamically unstable patients
 who
 are at high risk for 
surgery (Class IIb) [8]. BAV is frequently used as a bridge to 
AVR in patients with severe AS and New York Heart 
Association Class III-IV heart failure as improved hemo-
dynamics likely decrease the risk of surgery [7, 8].  
  BAV is also a class IIb indication by the present 
ACC/AHA guidelines for palliation
 when surgery cannot be 
performed secondary to serious co-morbidities [8], but the 
indications for performing palliative procedures is unclear. 
Although there is minimal data that these high-risk 
procedures prolong life [8], these inoperable patients have 
limited options, and there is no medical treatment available 
that improves survival [8]. In fact, medications that alleviate 
pulmonary edema by decreasing preload and central volume 
can also result in excessive reductions in preload and an 
unsafe drop in cardiac output [8].  
  Percutaneous AVR is a developing technology that might 
be an alternative treatment in high-risk inoperable patients 
with severe AS, but its safety and efficacy remain contro-
versial. A self-expanding prosthetic valve can be deployed 
percutaneously via a retrograde approach in approximately 
84-93% of patients. When successfully implanted, it 
increases aortic valve area, reduces transvalvular gradients, 
and improves New York Heart Association functional class, 
but major adverse cardiac events occurred in as many as 
32% of patients at short term follow-up, which included 
death in 20% [10-12]. The largest trial to date which 
included 86 patients reported a procedural mortality of 6%, a 
30-day mortality of 12%, and a cumulative incidence of 
death, stroke, and myocardial infarction of 22% [12]. 
Percutaneous AVR is also limited by bleeding (24%) and 
paravalular leakage (48%) and might be less successful in 
the setting of a bicuspid aortic valve [13]. While previous 
trials investigating percutaneous AVR are small, non-rando-
mized, and lack long term follow-up, there still is enthusiasm 
for this emerging technology; however, its role in clinical 
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  Patients with symptomatic co-existing severe coronary 
artery disease, severe AS, and heart failure are frequently 
deemed to be poor surgical candidates, but these high-risk 
patients have percutaneous options. According to several 
case reports, BAV can be safely performed 1-2 weeks prior 
to percutaneous coronary interventions (PCI) in patients with 
severe AS, refractory heart failure with LV dysfunction, and 
coronary artery disease who are not considered to be surgical 
candidates for AVR and coronary artery bypass grafting [1, 
14, 15]. For example, an elderly male with severe AS, chest 
pain, and NYHA class IV heart failure underwent BAV 
followed by successful LM stenting within 1 week [1].  
  There is even some data supporting the safety of 
performing these high-risk interventions at the same time. In 
the Spanish literature, a morbidly obese 65-year-old female 
successfully underwent combined BAV and ostial left cir-
cumflex stenting prior to bariatric surgery. AVR and coro-
nary artery bypass grafting were then performed 4 months 
later [16].  
  In addition to case reports, several small cohorts have 
also demonstrated the safety and utility of combining 
palliative percutaneous BAV with coronary artery inter-
ventions [1, 14, 15, 17, 18]. Combined BAV with single 
vessel coronary angioplasty was performed in 9 patients with 
critical AS, chest pain, and heart failure. 8 out of 9 patients 
had marked improvement in symptoms at discharge. PCI 
was done on the LAD (n = 3), left circumflex (n = 3), right 
coronary artery (n = 2), and a saphenous vein graft to the 
right coronary artery (n = 1). Complications included 2 groin 
hematomas, 1 transient left bundle branch block, and 1 case 
of transient atrial fibrillation [17]. Combined BAV and PCI 
were performed successfully in 17 other patients at a 
different medical center. PCI was done prior to BAV in 13 
patients and after BAV in another 4 cases without peri-
procedural mortality, myocardial infarction, or stroke [18]. 
While these single center experiences demonstrated that 
performing combined BAV and PCI in inoperable patients is 
a viable option, these studies failed to include LM 
interventions, and to our knowledge, our case is the first to 
demonstrate the safety of combined BAV and LM stenting in 
the English literature. Further studies are clearly warranted.  
  Furthermore, the decision to treat the valve first or the 
coronaries first has not been addressed and remains unclear. 
In our experience we believe that clinical presentation and 
anatomy should dictate management. For example, patients 
presenting primarily with heart failure and volume overload 
in the setting of severe untreated AS appear to have a dismal 
prognosis when they suffer myocardial ischemia during 
complex PCI. Thus, we recommend performing percuta-
neous BAV prior to PCI in these patients as this approach 
likely reduces the risk of the procedure by unloading the LV, 
decreasing diastolic wall stress, prolonging
 diastolic perfu-
sion time, and increasing coronary flow reserve. This 
approach also allows more time for complicated PCI 
especially in the setting of complex unprotected LM sten-
ting. However, if an inoperable patient with severe AS, 
congestive heart failure, and severe CAD presents with an 
acute coronary syndrome and has anatomy suitable for 
uncomplicated stenting, perhaps PCI should be performed 
prior to BAV. Nevertheless, the question as to which should 
be addressed first remains unanswered. 
CONCLUSIONS 
  Combined palliative BAV and LM stenting is a viable 
option in inoperable patients with severe AS, severe 
coronary artery disease, and heart failure with depressed LV 
systolic function. While AVR and coronary artery bypass 
grafting remain the superior option, it is reasonable to offer 
these high-risk patients a combined palliative percutaneous 
procedure for symptomatic relief. Given the paucity of data, 
certainly further investigation is warranted as to whether the 
aortic valve or coronary artery should be addressed first. 
ABBREVIATIONS 
LV  =  Left ventricular  
AS =  Aortic  stenosis 
LAD  =  Left anterior descending artery coronary artery 
LM =  Left  main 
AVR  =  Aortic valve replacement 
BAV  =  Balloon aortic valvulplasty  
PCI =  Percutaneous  coronary  interventions   
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